Table 1.
Summary of clinical data from case reports published between 2019 and 2024 describing the use of ALK inhibitors in patients with EIMS.
| First author | Year of publication | Age at diagnosis | Involved region/organ | Treatment methods | Survival/follow-up information | Reference |
|---|---|---|---|---|---|---|
| Xiaojing Xu | 2019 | 28 | Abdomen and pelvis | - Crizotinib - Brigatinib |
3 years (alive) | Xu et al. 25 |
| Shijie Zhang | 2019 | 46 | Abdomen | - Surgical resection - Crizotinib - Anlotinib |
16 months (dead) | Zhang and Wang 26 |
| Shefali Chopra | 2021 | 72 | Central nervous system | - Surgical resection - Alectinib |
4 months (alive) | Chopra et al. 8 |
| Zhan Wang | 2022 | 42 | Pelvis, peritoneal metastasis | - Surgical resection - Crizotinib - Alectinib - Ceritinib - Lorlatinib |
3 years (alive) | Wang et al. 13 |
| Priyanka Singh | 2022 | 25 | Lungs | - Crizotinib - Surgical resection |
3 years (alive) | Singh et al. 24 |
| Mengmeng Li | 2023 | 31 | Abdomen | - Surgical resection - Ensartinib |
1 year (alive) | Li et al. 10 |
| XiaoQing Li | 2023 | Middle-aged | Gastric | - Surgical resection - Chemotherapy - Anlotinib - Ensartinib |
2 year (alive) | Li et al. 23 |
| Soheila Aminimoghaddam | 2023 | 20 | Tight ovary, uterus, and peritoneum | - Surgical resection - Crizotinib - Chemotherapy |
8 months (dead) |
Aminimoghaddam and Pourali 22 |
| Yang Zheng | 2024 | 34 | Mediastinum | - Lorlatinib, - Surgical resection |
2 years (alive) | Zheng et al. 27 |
| Our patient | 2024 | 18 | Abdomen and pelvis | - Surgical resection - Chemotherapy - Crizotinib - Alectinib - Lorlatinib |
59 months since the initial diagnosis (alive) | – |
ALK, anaplastic lymphoma kinase; EIMS, epithelioid inflammatory myofibroblastic sarcoma.